Asarina Pharma AB (publ) Share Price Nasdaq Stockholm
Equities
SE0011641794
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 21.03M 221M 1.76B |
---|---|---|---|---|---|
Net income 2021 | -31M -326M -2.59B | Net income 2022 | -13M -137M -1.09B | EV / Sales 2021 | - |
Net cash position 2021 | 16.42M 172M 1.37B | Net cash position 2022 | 13.58M 143M 1.13B | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.15
x | P/E ratio 2022 |
-1.31
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.98% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Nordkild
CEO | Chief Executive Officer | 69 | 01/16/01 |
Director of Finance/CFO | 69 | 01/17/01 | |
Public Communications Contact | 63 | 01/11/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul de Potocki
CHM | Chairman | 62 | 01/18/01 |
Public Communications Contact | 63 | 01/11/01 | |
Marianne Kock
BRD | Director/Board Member | 69 | 01/18/01 |
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
-12.75% | 22.22B | |
+5.07% | 22.94B | |
-39.94% | 16.87B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |